GN Hortobagyi

S3-7: Everolimus for Postmenopausal Women with Advanced Breast Cancer: Updated Results of the BOLERO-2 Phase III Trial.

GN Hortobagyi, Martine Piccart, Hope S. Rugo et al. · Cancer Research · 2011 · 44 citations

Medicine, Oncology, Pharmacology +17

Abstract OT1-02-04: SWOG S1418/NRG -BR006: A randomized, phase III trial to evaluate the efficacy and safety of MK-3475 as adjuvant therapy for triple receptor-negative breast cancer with <u>&amp;gt;</u> 1 cm residual invasive cancer or positive lymph nodes (&amp;gt;pN1mic) after neoadjuvant chemotherapy

Lajos Pusztai, WE Barlow, PA Ganz et al. · Cancer Research · 2018 · 24 citations

Medicine, Oncology, Breast Oncology +16

Abstract S5-07: SWOG S0500 – A randomized phase III trial to test the strategy of changing therapy versus maintaining therapy for metastatic breast cancer patients who have elevated circulating tumor cell (CTC) levels at first follow-up assessment

JB Smerage, WE Barlow, DF Hayes et al. · Cancer Research · 2013 · 14 citations

Medicine, Oncology, Breast Oncology +14

Abstract PD4-06: First-line ribociclib + letrozole in hormone receptor-positive, HER2-negative advanced breast cancer: Efficacy by baseline circulating tumor DNA alterations in MONALEESA-2

GN Hortobagyi, Salomon M. Stemmer, Mario Campone et al. · Cancer Research · 2018 · 14 citations

Medicine, Oncology, Pharmacology +17

S1-1: A Phase III Randomized Trial of Anastrozole Versus Anastrozole and Fulvestrant as First-Line Therapy for Postmenopausal Women with Metastatic Breast Cancer: SWOG S0226.

Mehta Rs, WE Barlow, KS Albain et al. · Cancer Research · 2011 · 13 citations

Medicine, Oncology, Pharmacology +16